
“In April, an expert advisory panel for the FDA voted unanimously to recommend Epidiolex’s approval and determined that ‘CBD has a negligible abuse potential.’ The DEA did not immediately respond to Ars’ request for comment. But GW said it expects that the DEA will reschedule CBD within 90 days.”








